^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Yervoy (ipilimumab)

    i
    Other names: BMS-734016, MDX 101, MDX 010, MDX-CTLA-4, MDX-CTLA5, BMS734016, MDX-010, MDX010, BMS 734016
    Company:
    BMS, Ono Pharmaceutical
    Drug class:
    CTLA4 inhibitor
    Related drugs:
    13h
    SWOG S1609: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (clinicaltrials.gov)
    P2, N=818, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    PD-L1 overexpression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
    2d
    A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma (clinicaltrials.gov)
    P1/2, N=94, Recruiting, Ravi Amaravadi, MD | Trial completion date: Oct 2025 --> Jan 2027 | Trial primary completion date: Oct 2025 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • hydroxychloroquine
    3d
    C6461013: Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body. (clinicaltrials.gov)
    P1/2, N=138, Recruiting, Pfizer
    Trial initiation date
    |
    Yervoy (ipilimumab)
    4d
    Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN (clinicaltrials.gov)
    P1/2, N=54, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2026 --> May 2027
    Trial completion date • Checkpoint inhibition • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog)
    |
    PIK3CA mutation • PTEN mutation
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Aliqopa (copanlisib) • ABP 206 (nivolumab biosimilar)
    5d
    Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial. (PubMed, Nat Commun)
    We report on the randomized portion of the phase 2, open-label CheckMate 650 trial (NCT02985957), in which docetaxel-experienced, biologically male patients with chemotherapy-refractory metastatic castration-resistant prostate cancer were randomized 2:2:1:2 to nivolumab 3 mg /kg plus ipilimumab 1 mg /kg (n = 73), nivolumab 1 mg /kg plus ipilimumab 3 mg /kg (n = 74), ipilimumab 3 mg /kg (n = 38), or cabazitaxel (n = 74). Preliminary post hoc biomarker analyses in patients who received treatment with any immunotherapy regimen (i.e., treated with either of the nivolumab plus ipilimumab regimens or with ipilimumab alone, n = 12) identified a transcriptional signature, derived from the most highly expressed genes across cell types within select perivascular immune niches (comprising CD31+ endothelial, CD14+HLA-DR+ myeloid, and CD4+ and CD8+ T cells), which was associated with prolonged overall survival. These results provide further evidence of antitumor activity with nivolumab plus ipilimumab in select patients with metastatic castration-resistant prostate cancer and nominate a candidate prognostic biomarker that warrants confirmation in future prospective clinical trials.
    P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD14 (CD14 Molecule) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • docetaxel • cabazitaxel
    6d
    Computational insights into the pH-dependent behavior of Ipilimumab-CTLA-4. (PubMed, Phys Chem Chem Phys)
    Decomposition analysis on binding energy further indicated that the overall antigen-binding mode was maintained, whereas the introduced charged residues modulated local interaction strengths. These results provide mechanistic insights into how targeted mutations modulate pH-dependent recognition, offering a framework for the rational design of safer therapeutic antibodies.
    Journal • IO biomarker
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    Yervoy (ipilimumab)
    6d
    A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: May 2030 --> Aug 2030 | Initiation date: May 2026 --> Aug 2026 | Trial primary completion date: May 2026 --> Aug 2030
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    DNAJB1 (DnaJ Heat Shock Protein Family (Hsp40) Member B1) • PRKACA (Protein Kinase CAMP-Activated Catalytic Subunit Alpha)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • sirpiglenastat (DRP-104) • Hiltonol (poly-ICLC)
    7d
    ADAPT-IT: A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy (clinicaltrials.gov)
    P2, N=70, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    7d
    NIVIPI-Brain: Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases (clinicaltrials.gov)
    P2, N=71, Active, not recruiting, Fundación GECP | Trial primary completion date: Mar 2026 --> Oct 2027 | Trial completion date: Dec 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • paclitaxel • pemetrexed
    7d
    IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | N=60 --> 20 | Trial completion date: May 2026 --> Apr 2027 | Trial primary completion date: May 2026 --> Apr 2027
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Checkpoint inhibition • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD123 (Interleukin 3 Receptor Subunit Alpha) • IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    8d
    NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P2, N=20, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Sep 2030 --> Dec 2028 | Trial primary completion date: Sep 2030 --> Dec 2028
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • NC410
    8d
    TOP2101: A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC (clinicaltrials.gov)
    P2, N=19, Terminated, Eziafa Oduah, MD, PhD, MPH | N=38 --> 19 | Active, not recruiting --> Terminated; Slow enrollment.
    Enrollment change • Trial termination
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Repatha (evolocumab)